Erasca Secures U.S. Patent for Pan-KRAS Inhibitor ERAS-4001 Through 2043
Erasca’s U.S. Patent No. 12,552,813 grants composition-of-matter protection for its pan-KRAS inhibitor ERAS-4001 until at least June 2043. The company expects initial Phase 1 monotherapy data for ERAS-0015 in 1H 2026 and for ERAS-4001 in 2H 2026.
1. Patent Issuance and Coverage
The U.S. Patent and Trademark Office granted Erasca Patent No. 12,552,813 covering ERAS-4001 and related compositions with composition-of-matter protection through at least June 2043, subject to potential term extensions. This exclusivity positions ERAS-4001 for protected market entry and reduces generic competition risk.
2. Strengthening RAS Franchise and IP Portfolio
This patent expands Erasca’s diversified intellectual property portfolio for RAS-driven cancers, complementing its first-in-class ERAS-4001 and best-in-class pan-RAS molecular glue ERAS-0015. Additional patent applications pending further bolster the company’s long-term IP foundation.
3. Upcoming Phase 1 Data Milestones
Erasca plans to report initial monotherapy Phase 1 data for ERAS-0015 in the first half of 2026 and for ERAS-4001 in the second half of 2026, marking critical clinical catalysts. Successful readouts could validate the RAS/MAPK pathway strategy and drive investor sentiment.
4. ERAS-4001 Preclinical Profile
ERAS-4001 demonstrated single-digit nanomolar IC50s against both GTP- and GDP-bound KRAS mutants, induced tumor regressions across multiple KRAS-mutant models, and exhibited favorable ADME/PK characteristics, with no activity against HRAS or NRAS, suggesting a potentially enhanced therapeutic window.